NASDAQ$NXTC
NextCure Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
NextCure reported financial results for the third quarter of 2021 and provided a business update.
NextCure reported its third quarter 2021 financial results and provided a business update, highlighting upcoming presentations of clinical and biomarker data for its NC318 and NC410 programs at the SITC annual meeting.
- Presented clinical and biomarker data for NC318 and NC410 programs at the SITC annual meeting.
- Hosted a virtual research and development update event following the SITC conference on November 15th.
- Dr. Roy Herbst highlighted the significant remaining unmet need in the treatment of lung cancer at the R&D update event.
- Dr. Herbst is a collaborator in the Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with advanced non-small cell lung cancer.
Headline financials
Revenue & EPS history
NextCure · Revenue · Quarterly
$22.4M
Forward guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.7%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-1.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+34.8%
Q4 2023
Best reaction
-19.8%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.9% | +6.6% | -16.0% | |
| Q3 2025 | -8.8% | -5.4% | +25.6% | |
| Q2 2025 | -4.4% | +1.9% | -4.8% | |
| Q2 2024 | -1.2% | +1.9% | -4.8% | |
| Q1 2025 | -7.7% | -20.8% | +2.5% | |
| Q4 2024 | +6.1% | -1.7% | -37.7% | |
| Q3 2024 | -1.5% | +18.0% | -12.6% | |
| Q1 2024 | +11.7% | +15.3% | +12.4% | |
| Q4 2023 | +34.8% | +39.7% | +13.5% | |
| Q3 2023 | +10.3% | +6.5% | +12.1% | |
| Q2 2023 | -2.9% | -2.3% | -18.9% | |
| Q1 2023 | +4.6% | +14.5% | +14.5% | |
| Q4 2022 | -4.5% | -5.1% | -5.7% | |
| Q3 2022 | -19.8% | -31.2% | -42.9% | |
| Q2 2022 | +9.8% | +14.0% | -5.1% | |
| Q1 2022 | -4.5% | -15.1% | +4.8% | |
| Q4 2021 | -1.4% | +0.4% | +2.7% | |
| Q3 2021 | -1.4% | -23.5% | -34.5% | |
| Q2 2021 | +5.8% | +3.2% | +7.5% | |
| Q1 2021 | +3.4% | +5.0% | -1.0% | |
| Q4 2020 | -2.0% | +2.1% | -12.7% | |
| Q3 2020 | -4.3% | +0.9% | +11.0% | |
| Q2 2020 | -1.3% | -3.1% | -14.2% | |
| Q1 2020 | +12.2% | +4.0% | -24.8% | |
| Q4 2019 | -12.3% | +4.0% | +5.2% | |
| Q3 2019 | -3.3% | -7.6% | +31.3% | |
| Q2 2019 | +11.7% | +11.1% | +53.9% | |
| Q1 2019 | -6.8% | -6.3% | +0.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro